Altacar

Single agent therapy for complicated skin & skin structure infections in adult & ped ≥3 mth, complicated intra-abdominal infections in adult & ped, & bacterial meningitis in childn ≥3 mth.

Adult Skin & skin structure infection 500 mg every 8 hr by IV infusion over 15-30 min. Infection caused by P. aeruginosa 1 g every 8 hr by IV infusion over 15-30 min. Intra-abdominal infection 1 g every 8 hr by IV infusion for over 15-30 min, or 1 g every 8 hr by IV bolus inj (5-20 mL) over 3-5 min. Adult w/ renal impairment CrCl >50 mL/min 500 mg (cSSSI) & 1 g (intra-abdominal) every 8 hr, 26-50 mL/min Recommended dose every 12 hr, 10-25 mL/min ½ recommended dose every 12 hr, <10 mL/min ½ recommended dose every 24 hr. Ped ≥3 mth w/ normal renal function IV infusion is to be given over approx 15-30 min. IV bolus inj (5-20 mL) is to be given over approx 3-5 min. Complicated skin & skin structure infection 10 mg/kg every 8 hr. Max: 500 mg. Infection caused by P. aeruginosa 20 mg/kg (or 1 g in ped >50 kg) every 8 hr. Intra-abdominal infection 20 mg/kg every 8 hr. Max: 1 g. Meningitis 40 mg/kg every 8 hr. Max: 2 g. Ped <3 mth w/ complicated intra-abdominal infection & normal renal function IV infusion is to be given over 30 min: Infant ≥32 wk gestational age (GA) & postnatal age (PNA) ≥2 wk 30 mg/kg every 8 hr, ≥32 wk GA & PNA <2 wk 20 mg/kg every 8 hr, <32 wk GA & PNA ≥2 wk 20 mg every 8 hr, <32 wk GA & PNA <2 wk 20 mg/kg every 12 hr.

Hypersensitivity to carbapenem or β-lactams.

Immediately discontinue use if an allergic reaction occurs. May need to discontinue use in suspected or confirmed Clostridium difficile-associated diarrhea (CDAD). For IV use only. Seizures & other adverse CNS experiences most commonly in patients w/ CNS disorders (eg, brain lesions or history of seizures) or w/ bacterial meningitis &/or compromised renal function. Use in absence of a proven or strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit & increases risk of development of drug-resistant bacteria. Prolonged use may result in overgrowth of non-susceptible organisms. Periodically assess organ system functions including renal, hepatic, & hematopoietic during prolonged therapy. Not recommended in concomitant use w/ valproic acid or divalproex Na. Adverse events (eg, seizures, headaches &/or paresthesias) may develop that could interfere w/ mental alertness &/or cause motor impairment. Thrombocytopenia w/o clinical bleeding are observed in renal impairment. Inadequate information on use in patients on hemodialysis or peritoneal dialysis. Should not be used during pregnancy unless clearly needed. Caution during lactation. No experience in ped w/ renal impairment.

Hypersensitivity reactions, CDAD, development of drug-resistant bacteria, overgrowth of non-susceptible organisms, potential seizure & neuromotor impairment.

Increased plasma conc w/ probenecid. Reduced conc of valproic acid.

Other Beta-Lactams

Rx